TTR and amyloidosis: The first clinical trial involving systemic delivery of CRISPR components used SpCas9 and a sgRNA targeting TTR (NTLA-2000) to reduce the production of misfolded transthyretin protein in hereditary transthyretin amyloidosis (Gillmore et al., 2021).